All In Biotech

Drug Trial Radar · NCT05056974

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

A Phase II Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs Among ART Stabilized HIV-1 Patients Who Undergo ART Interruption

Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

11

Actual

Start

Dec 2, 2021

Primary completion

Feb 1, 2023

Study completion Feb 1, 2023

Sponsor

Lead sponsor
United BioPharmaIndustry
Sponsor type
Industry
First posted
Sep 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo ART interruption.

Conditions

  • HIV-1 Infection

Interventions

  • UB-421Biological

    10 mg/kg, weekly UB-421 during the 8-week

  • chidamideDrug

    10 mg/dose, twice a week for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HIV cell-associated RNA levelsTime frame: Post-treatment weeks up to 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.